Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report
about
Mesothelioma treatment: Are we on target? A reviewLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesMalignant pleural mesothelioma: an update on diagnosis and treatment options.New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.The role of interleukin-6 in malignant mesotheliomaTreatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lungCross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.Searching for targets for the systemic therapy of mesothelioma.Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review.Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.Advances in treatment of mesothelioma.Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.Advances in systemic therapy for malignant mesothelioma: future perspectives.Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.Medical treatment of malignant pleural mesothelioma relapses.Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
P2860
Q26800042-0B507301-977C-4B2F-BE57-7953B128F74BQ28395597-8BDE29A5-344C-449E-89C4-FFEC66CC5272Q34513958-DEAA2581-C3F0-4EC9-B7EE-94DD56692F23Q35042668-120FA5AC-D0B9-443D-9F52-0BA7529CC96BQ35200628-D95075E7-07F2-43C9-AC71-E1697AF4E2BDQ37241709-09E95896-97ED-454E-B848-5E0359DC4924Q37684642-23CE104C-736D-478C-8699-8686CE69EB6FQ38365768-55AB51A1-6849-4C37-BD87-A211CFB1AA39Q38586323-DD969D03-6786-4CBC-8114-6C3BDC738A0FQ38758684-61BD05EF-90AA-4DD6-86D8-594342AE9EC0Q38800916-EBFFF02C-5468-419B-B84C-27EC526E65B6Q38815319-BDCE1113-81A2-441F-AEA8-31A219DCC852Q38815335-0E6B1E75-18EE-44F7-9989-06DBD94BFC8BQ39621469-483F4784-83C9-43B8-BE5E-96FCD38B2CCFQ43993005-3A30C991-49F4-4EE0-AFE0-281F34742B5AQ47912434-55883A08-94EA-4854-A544-0D2931AC9B52Q52642770-572B43DA-E756-41DE-9E8E-0CCEB21C5246Q52672887-9A131C92-A9C4-44EC-99FD-3EFDA6510C5DQ52672891-43F4A530-CD06-408C-A3F3-A436973B35FDQ57822522-A1A15679-C816-4B93-9B86-CA2A7BF41585
P2860
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase II study of dasatinib in ...... group B 30601): a brief report
@ast
Phase II study of dasatinib in ...... group B 30601): a brief report
@en
type
label
Phase II study of dasatinib in ...... group B 30601): a brief report
@ast
Phase II study of dasatinib in ...... group B 30601): a brief report
@en
prefLabel
Phase II study of dasatinib in ...... group B 30601): a brief report
@ast
Phase II study of dasatinib in ...... group B 30601): a brief report
@en
P2093
P2860
P1476
Phase II study of dasatinib in ...... group B 30601): a brief report
@en
P2093
Arkadiusz Z Dudek
Gregory A Otterson
Hedy L Kindler
Herbert Pang
Lydia Hodgson
Robert A Kratzke
P2860
P304
P356
10.1097/JTO.0B013E318248242C
P577
2012-04-01T00:00:00Z